AstraZeneca To Invest $2.5B In China Research Hub <https://www.law360.com/mergersacquisitions/articles/2314010?nl_pk=34b724c6-95c5-49a3-b963-aea9d35fbb95&utm_source=newsletter&utm_medium=email&utm_campaign=mergersacquisitions&utm_content=2025-03-24&read_main=1&nlsidx=0&nlaidx=1>
By Jade Martinez-Pogue Pharmaceutical giant AstraZeneca on Friday announced plans to invest $2.5 billion in Beijing over the next five years to establish a new global strategic research and development center, inking agreements with three biotechs to help develop new treatments and advance life sciences in China. Read full article » <https://www.law360.com/mergersacquisitions/articles/2314010?nl_pk=34b724c6-95c5-49a3-b963-aea9d35fbb95&utm_source=newsletter&utm_medium=email&utm_campaign=mergersacquisitions&utm_content=2025-03-24&read_more=1&nlsidx=0&nlaidx=1> | Save to favorites » <https://www.law360.com/mergersacquisitions/articles/2314010?nl_pk=34b724c6-95c5-49a3-b963-aea9d35fbb95&utm_source=newsletter&utm_medium=email&utm_campaign=mergersacquisitions&utm_content=2025-03-24&read_later=1&nlsidx=0&nlaidx=1>
